Pooled brain scan data from 11 psychedelic studies finds a shared connectivity pattern

The question

Do different psychedelic drugs change brain activity in the same way? The researchers asked whether a common pattern shows up once data from many separate imaging studies are analyzed together.

What they did

The team combined 11 independent resting-state functional MRI datasets — brain scans taken while people lie still and let their minds wander — covering five psychedelics: psilocybin, LSD, mescaline, DMT and ayahuasca. The datasets came from research groups in five countries across three continents. All the scans were processed through one identical pipeline, then analyzed with a statistical approach (Bayesian hierarchical modelling) designed to handle differences between sites and drugs.

What they found

The most consistent finding was increased communication between ‘transmodal’ brain networks involved in higher-order thinking (default, frontoparietal and limbic) and ‘unimodal’ sensory networks (visual and somatomotor). Deep brain regions — the thalamus, caudate and putamen — and the cerebellum also showed altered coupling with sensorimotor networks. In contrast to several individual studies, the pooled analysis found only weak-to-moderate and selective reductions in connectivity within networks, and these varied substantially across drugs and networks.

The fine print

The abstract does not report how many people were scanned in total, nor the doses, session details or whether placebo comparisons were used in each contributing dataset. The outcome is brain connectivity during acute drug effects, not symptoms, wellbeing or any clinical benefit, so it cannot tell us whether these changes help anyone. Combining datasets collected under different protocols introduces variability that statistical modelling can reduce but not remove. This summary is based on the abstract only.

What it means

Across several different psychedelics and research sites, the drugs appear to loosen the usual separation between thinking networks and sensory networks in the brain. This is a map of what the drugs do to brain activity, not evidence about whether they help with any health condition.

Evidence grade: Low. A pooled re-analysis of existing brain imaging datasets measuring brain connectivity rather than clinical outcomes, with no participant total reported in the abstract.

This summary is based on the study’s published abstract.